Public consultation on interim decisions to amend the Poisons Standard - ACMS, ACCS & Joint ACMS-ACCS JUNE, 2024
Overview
Interim decisions regarding substances discussed at the expert advisory meetings.
This consultation is for interim decisions made in relation to substances that were discussed at the JUNE 2024 meetings of the Advisory Committee on Medicines Scheduling (ACMS) and the Advisory Committee on Chemicals Scheduling (ACCS).
Kindly note that the interim decisions published below may differ from the initial proposal. Please read through the proposed interim decisions which can be accessed through the links below and are available on the consultation page for your convenience.
Once you are familiar with the interim decision, please provide your comments and votes in relation to the interim decision.
The closing date for this consultation is close of business 18 OCTOBER 2024. All submissions received by the deadline will be considered by the delegate before they make an interim decision.
The interim decisions under consultation are detailed in the Public notice of interim decisions JUNE 2024 which can be accessed below:
Substances for which public comment is sought:
ACMS
- sildenafil
ACCS
- allyl esters
- glyoxylic acid
JOINT ACCS-ACMS
- intravenous potassium salts (interim decision delayed)
- sulfonamides
The interim decision has been delayed for intravenous potassium salts that was referred to the joint ACCS-ACMS meeting.
Audiences
- Aboriginal and Torres Strait Islander People
- Seniors
- Men
- Women
- Carers and guardians
- Families
- Parents
- Young people
- Academics
- Non-government organisations
- State government agencies
- Commonwealth agencies
- Local governments
- Health professionals
- Health workforce
- General public
- Community groups
- Businesses
- Contracted Service Providers
- Aged care service providers
- Aged care workforce
- Aged care professionals
- BPRU staff
- Graduates
- Online and Publications staff
- Secretariat
- PCCD
- Health staff
- HPRG (TGA) Staff
- Prescription medicines
- Complementary medicines
- Over-the-counter medicines
- Medical Devices & IVDs
- Biologicals
- Other
Interests
- Policy Development
Share
Share on Twitter Share on Facebook